Share |

pharmaceutical

FB Roundup: SP Hinduja, Grifols family, Carlos Slim

May 22, 2023

In this week’s FB Roundup, tributes are paid to SP Hinduja, the head of Britain's richest family; Spain's Grifols ends family leadership as new CEO is named; and Carlos Slim buys a stake in a Mexican oilfield.

Tributes paid to SP Hinduja, the head of Britain's richest family
SP [Srichand Parmanand] Hinduja, the billionaire leader of the Hinduja Group conglomerate and head of Britain's richest family has died at the age of 87.

Described as a “visionary titan of industry and business”, the hugely successful businessman “passed away peacefully”, according to a family spokesperson.

Dr. David Brown: How Viagra opened the doors to machine learning innovation

March 17, 2023

In an exclusive interview with Campden FB, Dr. David Brown talks about his passion for entrepreneurialism, the mind-blowing benefits of machine learning and how big pharma needs a change in mindset…

Throughout his storied career, Dr. David Brown has made significant contributions to medical research within the pharmaceutical industry, but perhaps his most famous innovation came about through a chance observation when the angina medication he was working on had unexpected applications.

While working for Pfizer, he was named co-inventor on the patent for Viagra and, for eight years, led the team that developed the hugely successful erectile dysfunction medication into one of the bonanza breakthroughs of the century.

Victoria Engelhorn: Becoming more than her family name

February 16, 2023

A beneficiary of the sale of her family’s multi-generational pharmaceutical companies, Victoria Engelhorn was determined to take the opportunity to grow, realise her own dreams and give back to society. In an exclusive interview with Campden FB, she reveals how forging her own socially responsible path gave her meaning and purpose.

The granddaughter of billionaire German businessman Curt Engelhorn, great-great granddaughter of Friedrich Engelhorn (the founder of chemical giant BASF) and the beneficiary of a family-wide windfall, Victoria Engelhorn understands all too well the heft and privilege of inheriting great wealth.

Fearless entrepreneur: Werner Tschollar on breakthroughs in biotech and staying small and flexible in business

February 16, 2022

For nearly three decades, Dr. Werner Tschollar has been at the forefront of the pharmaceutical, biotech and financing industries. With a humanitarian approach to life and a savvy head for business, he has parlayed his extensive credentials and experience into a series of innovative products and treatments that have changed the quality of life for countless people.

Why the grass is greener for family investors in the legal cannabis market

November 26, 2020

The growing global $344 billion legal cannabis market is maturing, attracting sophisticated capital and proving attractive for family office investors seeking returns, says Chrystal Capital Partners.

The growing global $344 billion legal cannabis market is maturing, attracting sophisticated capital and proving attractive for family office investors seeking returns, says Chrystal Capital Partners.

Kingsley Wilson (pictured above), investment partner and co-founder of the London-based entrepreneurial corporate finance and investment house, discusses the opportunities and shatters the myths in the alternative asset class with Geordie Hadden-Paton (pictured below), investment associate at CCP.

Dr Annalisa Jenkins on healthcare and biotech investments for family offices

April 28, 2020

The coronavirus pandemic has triggered a race for disruptive innovation in diagnostics, new therapies and novel vaccines, but the global life sciences industry was already expected to reach more than $2 trillion in gross value by 2023, up from $1.6 trillion before the crisis.

Funding the frontier of new drug discovery

April 25, 2019

How is one Chinese biotechnology group succeeding in supporting the earliest stage of new drug discovery when global pharmaceutical companies have given up? Dr Jun Mao, founder and chairwoman of Viva Ventures, explains how it leverages its in-house expertise to invest in hundreds of biotech startups in the $20 trillion global pharmaceutical and biotechnology market.

Viva Ventures has a long history in supporting drug discovery for disease cures in China and the United States, can you explain more about the market opportunity?

Dr Reddy’s Laboratories: A good example of succession planning

January 25, 2012

Relinquishing control can often be difficult for company founders, but one Indian family business head is currently in the process of ensuring succession at his firm goes well.

A picture of health?

July 1, 2007

With a production cycle lasting a decade and large conglomerates threatening to swoop, it can be difficult for family-owned pharmaceutical companies to remain both profitable and independent. Andrea Chipman talks to a select few who have made it – Roche, Boehringer, Servier and Stiefel – to learn their strategies for success

Andrea Chipman is a freelance journalist based in the UK.

In 2006, the pharmaceutical sector saw another round of consolidation as industry giants gobbled up medium-sized players that had struggled to remain on their own.